It is estimated that 0.4% of GDP in Mexico is destined for the attention of musculoskeletal diseases. Osteoarthritis (OA) is one of the main causes of disability after 40 years of age.
Therefore, multimodal treatment that includes pharmacological and non-pharmacological measures, from the more traditional such as analgesics and the most recent such as viscosupplementation, is important, noted the Mexican Initiative for Patients with Osteoarthritis and Rheumatoid Arthritis (IMPACTAR).
Healthy Joints By Life’s Armour | High Potency Joint Support Supplement Vitamin With Glucosamine & Msm For Joint Mobility, Health, Flexibility, Pain, Increased, Strength & Lubrication
At the press conference to announce the actions of IMPACTAR to celebrate the World Day for Rheumatic Diseases, Dr. Fernando Torres Roldán, President of the Mexican College of Orthopedics and Traumatology (CMOT), said that the prevalence of osteoarthritis, and in general of this group of ailments, has as a consequence physical, social and economic problems, both within the family and for health institutions. " By 2050 it is expected that the number of people over 60 will triple, since Mexico ranks sixth in terms of aging ."
OA is a chronic inflammatory condition that causes degeneration in the joints, mainly of the hip, hands, knees, lower back (back) and neck. It is estimated that it affects approximately 2.5 million people in Mexico, with a prevalence of 10.5% of the population and this is due to wear in the upper layer of cartilage that generates friction between the bones of the joint. It manifests clinically in pain, swelling and loss of movement.
It is estimated that rheumatic diseases diminish up to seven healthy years and in women the reduction is up to 13 years. These are problems that derive from total or partial disability caused by these diseases, because they generate high economic costs, due to the type of specialized care that includes the use of orthopedic devices and rehabilitation therapies, as well as the payment of subsidies and disability pensions. There lies the importance of adequately treating patients with options that slow the progression of the disease and provide them with quality of life, said Dr. Torres Roldán.
The specialist said that the management of patients with OA has evolved both from the diagnostic and therapeutic point of view, due to scientific advances on pharmacological interventions increasingly effective and safe to improve joint function and reduce pain caused by the deterioration of joints in patients. " There are new treatment patterns, such as viscosupplementation, which consists of the infiltration of a viscous and elastic substance with properties similar to those of synovial fluid in healthy patients, which have favorably contributed to optimizing the condition of the affected joint, especially on the knees".
In addition to the presentation of these new treatment patterns obtained through various studies and the research protocol carried out by the Initiative, the IMPACTAR race was announced, aimed at raising awareness about joint care, mainly in the knees. "We call on society in general to join in the race to be held on October 17, in the second section of Bosque de Chapultepec, to offer information about these diseases and the impact of the lack of timely diagnosis and treatment, as well as as in the quality of life of patients .